Shares are trading at $1.57 quite a bit above the 50 day moving average of $1.20 and which is quite a bit above the 200 day moving average of $1.14. The 50 day moving average moved up $0.37 whereas the 200 day average was up by +37.90%. Trading volume for Alcobra Ltd. – Ordinary Shares was 1,083K on Tuesday. Volume was down 63.59% under the stocks average daily volume.
Short traders are more bullish on Alcobra Ltd. – Ordinary Shares lately if you take a look at the change in short interest. The stock realized a fall in short interest from September 29, 2017 to October 13, 2017 of -10.95%. Short interest fell from 824,301 to 734,070 over that timeframe. With short interest at 734,070 and short average daily volume at 979,867, the short-interest ratio is 1.0 and the percentage of shorted shares is 0.03% as of October 13.
Additionally, here are a few investment firms who have increased or decreased their stake in (ADHD). As of the end of the quarter Goldman Sachs Group Inc had sold 17,791 shares trimming its position 39.5%. The value of the company’s investment in Alcobra Ltd. – Ordinary Shares decreased from $51,000 to $30,000 a change of $21,000 quarter to quarter. As of quarter end Kingdon Capital Management, L.l.c. had disposed of a total of 50,479 shares trimming its holdings by 14.4%. The value of the investment in Alcobra Ltd. – Ordinary Shares went from $401,000 to $337,000 a change of 16.0% since the last quarter.
As of quarter end Panagora Asset Management Inc had acquired 265,202 shares growing its stake by 142.1%. The value of the total investment in Alcobra Ltd. – Ordinary Shares increased from $213,000 to $506,000 increasing 137.6% for the reporting period. As of the end of the quarter Two Sigma Investments, Lp had bought 700 shares growing its stake by 3.2%. The value of the investment in ADHD decreased from $25,000 to $25,000 decreasing 0.0% quarter over quarter.
On October 9 the stock rating was upgraded to “Speculative Buy” from “Hold” with a current price target of $2.00 in an announcement from WBB Securities.
As of the last earnings report the EPS was $-0.76 and is expected to be $-0.77 for the current year with 27,562,000 shares currently outstanding. Next quarter’s EPS is estimated at $-0.22 with next year’s EPS projected to be $-0.68.
Alcobra Ltd., a biopharmaceutical company, focuses on the development and commercialization of oral drug candidates. The company is primarily developing MDX (metadoxine), an onset/extended release formulation of the chemical pyridoxine pyroglutamate, which is in Phase III clinical trial for adults with attention deficit hyperactivity disorder (ADHD); in Phase II clinical trial for pediatric with ADHD; and which is completed Phase II clinical trial in adolescents and adults with Fragile X Syndrome. Alcobra Ltd. was founded in 2008 and is headquartered in Tel Aviv, Israel..